Balfour 2007a.

Methods	Double‐blinded RCT. Study start and end dates (November 2007 to February 2010) obtained from Clinicaltrials.gov
Participants	23 students (aged over 15 years) with symptoms of infectious mononucleosis for two weeks or less. Setting unclear. Of patients included in data analysis 12 were male and 9 female. Maximum age of participants was 24 years
Interventions	Valomaciclovir 2 g orally twice daily for 21 days, versus placebo
Outcomes	Number of participants with improvement in clinical symptoms and reductions in viral burden from baseline, number of participants who experienced adverse events
Notes	Unpublished study: data obtained from conference slides supplied by author and information on Clinicaltrials.gov
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	23 participants were enrolled, however 21 were included in data analysis. 2 participants were excluded; 1 due to not having a primary EBV infection and 1 as they had an adverse event on day 11. In reporting of SF12 questionnaires there are data missing from one of the placebo patients ‐ no details are given on why this might be the case
Selective reporting (reporting bias)	High risk	Clinical exam/symptom scores not individually reported; only reported as composite score of 10 parameters
Other bias	High risk	Unpublished trial, not peer reviewed Supported by an investigator‐initiated grant from Epiphany Biosciences